Quarterly pharmacy formulary change notice
|
|
- Quentin Stanley
- 6 years ago
- Views:
Transcription
1 Provider Bulletin June 2017 The formulary changes listed in the table below apply to all Anthem HealthKeepers Plus patients. These changes were reviewed and approved at the first quarter Pharmacy and Therapeutics Committee meeting held on March 29, Effective August 1, 2017, formulary changes, nonformulary changes and prior authorization requirements will apply. Therapeutic class LAMA and LAMA/LABA PRODUCTS THERAPY FOR ACNE ANTICOAGULANTS BETA AGONIST INHALERS BIPOLAR DISORDER DRUGS BIPOLAR DISORDER DRUGS Effective for all Anthem HealthKeepers Plus patients on August 1, 2017 Medication SPIRIVA 18 MCG CP-HANDIHALER DIFFERIN 0.1% GEL (OTC PRODUCT) COUMADIN TABLET (BRAND NAME ONLY) XOPENEX HFA INHALER EQUETRO CAPSULES Formulary status change WITH STEP THERAPY REVISE QL* 2 INHALER PER 30 WITH PRIOR AUTHORIZATION (PA) Potential alternatives (preferred products) SPIRIVA RESPIMAT 2.5 MCG INHALER SPIRIVA RESPIMAT 1.25 MCG INHALER WARFARIN TABLET JANTOVEN TABLET LITHIUM SOLUTION AFREZZA 90-4 UNIT AFREZZA 90-8 UNIT 6 BOXES PER 30 4 BOXES PER 30 The information in this bulletin may be an update or change to your provider manual. Find the most current manual at: HealthKeepers, Inc. is an independent licensee of the Blue Cross and Blue Shield Association. ANTHEM is a registered trademark of Anthem Insurance Companies, Inc. The Blue Cross and Blue Shield names and symbols are registered marks of the Blue Cross and Blue Shield Association. AVAPEC June 2017
2 Page 2 of 5 METRONIDAZOLE PROGESTINS METRONIDAZOLE BASAGLAR 100 UNIT/ML KWIKPEN LANTUS 100 UNITS/ML VIAL LANTUS SOLOSTAR 100 UNITS/ML HUMALOG 100 UNITS/ML VIAL HUMALOG 100 UNITS/ML KWIKPEN HUMALOG 200 UNITS/ML KWIKPEN HUMALOG 100 UNITS/ML CARTRIDGE HUMALOG MIX VIAL HUMALOG MIX VIAL HUMALOG MIX KWIKPEN HUMALOG MIX KWIKPEN HUMULIN VIAL HUMULIN N 100 UNITS/ML VIAL HUMULIN N 100 UNITS/ML KWIKPEN HUMULIN R 100 UNITS/ML VIAL HUMULIN 70/30 KWIKPEN LEVEMIR 100 UNITS/ML VIAL LEVEMIR FLEXTOUCH 100 UNITS/ML NOVOLOG 100 UNITS/ML FLEXPEN NOVOLOG 100 UNIT/ML VIAL NOVOLOG 100 UNIT/ML CARTRIDGE NOVOLOG MIX VIAL NOVOLOG MIX FLEXPEN SYRN NOVOLIN N 100 UNITS/ML VIAL NOVOLIN R 100 UNITS/ML VIAL NOVOLIN UNIT/ML VIAL RELION NOVOLIN N 100 UNIT/ML RELION NOVOLIN R 100 UNIT/ML RELION NOVOLIN VIAL HUMULIN R 500 UNITS/ML VIAL HUMULIN R 500 UNITS/ML KWIKPEN TOUJEO SOLOSTAR 300 UNITS/ML LIDOCAINE 5% LIDOCAINE 2% VISCOUS SOLN LIDOCAINE HCL 4% SOLUTION METRONIDAZOLE 1% GEL METRONIDAZOLE TOP 1% GEL PUMP HYDROXYPROGESTERONE 1.25 G/5ML MAKENA 1;250 MG/5 ML VIAL MAKENA 250 MG/ML VIAL LIDOCAINE HCL 4% SOLUTION LIDOCAINE 5% METRONIDAZOLE 1% GEL METRONIDAZOLE TOP 1% GEL PUMP HYDROCORTISONE 0.5% TRIAMCINOLONE ACETONIDE 0.5% TRIAMCINOLONE ACETONIDE 0.5% ADD QUANTITY LIMIT* (QL) 30 ML PER 30 REVISE QL* 21 ML PER 30 ADD QL 15 ML PER 30 5GMS PER DAY 10 GMS PER DAY WITH PA QL ADDED* 10 ML PER DAY QL REVISED* 5 GMS PER DAY 30 GMS PER 30
3 Page 3 of 5 ALCLOMETASONE DIPROPIONATE 0.05% ALCLOMETASONE DIPROPIONATE 0.05% HYDROCORTISONE BUTYRATE 0.1 % LOCOID 0.1% HYDROCORTISONE BUTYRATE 0.1 % LOCOID LIPO 0.1 % CLOBETASOL PROPIONATE 0.05% SOLUTION, NON-ORAL CORMAX 0.05% SOLUTION, NON-ORAL HALOBETASOL PROPIONATE 0.05 % ULTRAVATE 0.05 % HALOBETASOL PROPIONATE 0.05 % ULTRAVATE 0.05 % AMCINONIDE 0.1 % AMCINONIDE 0.1 % DESONIDE 0.05 % DESOWEN 0.05 % TRIDESILON 0.05 % DESONIDE 0.05 % LOTION DESOWEN 0.05 % LOTION DESONIDE 0.05 % DESOXIMETASONE 0.25 % TOPICORT 0.25 % DESOXIMETASONE 0.05 % GEL TOPICORT 0.05 % GEL DESOXIMETASONE 0.25 % TOPICORT 0.25 % DIFLORASONE DIACETATE 0.05 % PSORCON 0.05 % DIFLORASONE DIACETATE 0.05 % APEXICON E 0.05 % CUTIVATE 0.05 % FLUTICASONE PROPIONATE 0.05 % FLUTICASONE PROPIONATE % HALOG 0.1 % HALOG 0.1 % PANDEL 0.1 % CLOCORTOLONE PIVALATE 0.1 % CLODERM 0.1 % DERMATOP 0.1 % PREDNICARBATE 0.1 % DERMATOP 0.1 % PREDNICARBATE 0.1 % FOAM OLUX 0.05 % FOAM 45G MS PER GMS PER 30 60GMS PER 30 80GMS PER 30 90GMS PER GMS PER 30
4 Page 4 of 5 % % LOTION % LOTION TEMOVATE 0.05 % TEMOVATE 0.05 % CLOBETASOL E 0.05 % FLUOCINOLONE ACETONIDE 0.01 % SOLUTION, NON-ORAL SYNALAR 0.01 % SOLUTION, NON-ORAL FLUOCINOLONE ACETONIDE 0.01 % FLUOCINOLONE ACETONIDE % SYNALAR % FLUOCINOLONE ACETONIDE % SYNALAR % CAPEX SHAMPOO 0.01 % SHAMPOO FLUOCINONIDE 0.05 % FLUOCINONIDE 0.1 % VANOS 0.1 % HYDROCORTISONE VALERATE 0.2 % HYDROCORTISONE VALERATE 0.2 % FLUOCINONIDE 0.05 % SOLUTION, NON- ORAL FLUOCINONIDE 0.05 % GEL (GRAM) FLUOCINONIDE 0.05 % (GRAM) TRIANEX 0.05 % (GRAM) TRIAMCINOLONE ACETONIDE % TRIAMCINOLONE ACETONIDE 0.1 % TRIDERM 0.1 % TRIAMCINOLONE ACETONIDE % TRIAMCINOLONE ACETONIDE 0.1 % 120GMS PER GMS PER 30 DAY 240 GMS PER GMS PER GMS PER 30
5 VAGINAL ESTROGENS VAGINAL ESTROGENS XANTHINES XANTHINES Anthem HealthKeepers Plus Page 5 of 5 YUVAFEM 10 MCG VAGINAL INSERT PREMARIN VAGINAL ELIXOPHYLLIN 80 MG/15 ML ELIX (BRAND ONLY) THEO-24 ER MG CAPSULES (BRAND ONLY) WITH STEP THERAPY * Indicates no changes in Preferred/Nonpreferred status revision or addition to UM edit only. YUVAFEM 10 MCG VAGINAL INSERT 80 MG/15 ML SOLN 80 MG/15 ML SOLN ER TABLETS What action do I need to take? Please review these changes and work with your Anthem HealthKeepers Plus patients to transition them to formulary alternatives. If you determine formulary alternatives are not clinically appropriate for specific patients, you will need to obtain prior authorization to continue coverage beyond the applicable effective date. What if I need assistance? We recognize the unique aspects of patients cases. If your Anthem HealthKeepers Plus patient cannot be converted to a formulary alternative, call our Pharmacy department at and follow the voice prompts for pharmacy prior authorization. You can find the preferred drug list (formulary) on our provider website at If you need assistance with any other item, contact your local Provider Relations representative or call Provider Services at
Effective for all members on August 1, 2017
August 2017 Pharmacy Formulary Change Notice BlueChoice HealthPlan Medicaid is here to help you stay on top of your health care. We want to tell you about some upcoming changes to your Preferred Drug List
More informationThe Medical Letter. on Drugs and Therapeutics
The Medical Letter publications are protected by US and international copyright laws. Forwarding, copying or any other distribution of this material is strictly prohibited. For further information call:
More informationQuarterly pharmacy formulary change notice
Provider Bulletin April 2018 This table is used by HealthKeepers, Inc. to indicate formulary changes applicable to all Anthem HealthKeepers Plus members. These changes were reviewed and approved at the
More informationComparison of representative topical corticosteroid preparations (classified according to the US system)
Comparison of representative topical corticosteroid preparations (classified according to the US system) Potency group* Corticosteroid Vehicle type/form Trade names (United States) Available strength(s),
More informationQuarterly pharmacy formulary change notice
Provider Bulletin October 2018 Quarterly pharmacy formulary change notice The formulary changes listed in the table below apply to all Anthem HealthKeepers Plus patients. The changes listed in the table
More informationStep Therapy Requirements
An Independent Licensee of the Blue Cross and Blue Shield Association Step Therapy Requirements Effective: 05/01/2018 Updated 4/2018 H0302_2_2014 CMS Accepted 05/05/2014 1 BETA-BLOCKERS BYSTOLIC 10 MG
More informationMedication Policy Manual. Topic: Dupixent, dupilumab Date of Origin: March 10, Committee Approval: March 10, 2017 Next Review Date: May 2018
Independent licensees of the Blue Cross and Blue Shield Association Medication Policy Manual Policy No: dru493 Topic: Dupixent, dupilumab Date of Origin: March 10, 2017 Committee Approval: March 10, 2017
More informationQuarterly pharmacy formulary change
Medi-Cal Managed Care L. A. Care Major Risk Medical Insurance Program Provider Bulletin The formulary changes listed in the table below were reviewed and approved at our first-quarter 2018 Pharmacy and
More informationStep Therapy Criteria 2019
Step Therapy 2019 For information on obtaining an updated coverage determination or an exception to a coverage determination please call Freedom Health Member Services at 1-800-401-2740 or, for TTY/TDD
More informationDrug Class Literature Scan: Topical Steroids
Copyright 2012 Oregon State University. All Rights Reserved Drug Use Research & Management Program Oregon State University, 500 Summer Street NE, E35 Salem, Oregon 97301-1079 Phone 503-947-5220 Fax 503-947-1119
More informationMichigan Pharmacy and Therapeutics Committee September 9, 2014 at 6:00 PM Kellogg Center, East Lansing, Michigan
Michigan Pharmacy and Therapeutics Committee September 9, 2014 at 6:00 PM Kellogg Center, East Lansing, Michigan Agenda: Introductions Approval of Minutes of July 8, 2014 Meeting P & T Business Review
More informationQuarterly pharmacy formulary change notice
MEDICAID PROVIDER BULLETIN October 2018 The formulary changes listed in the table below were reviewed and approved at the second-quarter 2018 Pharmacy and Therapeutics Committee meeting. Effective October
More informationComparison of representative topical corticosteroid preparations (classified according to the US system)
Comparison of representative topical corticosteroid preparations (classified according to the US system) Potency group* Corticosteroid Vehicle type/form Trade names (United States) Available strength(s),
More informationQuarterly pharmacy formulary change notice
Quarterly pharmacy formulary change notice The formulary changes listed in the table below were reviewed and approved at our second quarter 2018 Pharmacy and Therapeutics Committee meeting. Effective October
More informationPharmacy Benefit Determination Policy
Policy Subject: Atopic Dermatitis Agents Policy Number: SHS PBD18 Category: Policy Type: Medical Pharmacy Department: Pharmacy Product (check all that apply): Group HMO/POS Individual HMO/POS PPO ASO s:
More informationEucrisa. Eucrisa (crisaborole) Description
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.90.25 Subject: Eucrisa Page: 1 of 6 Last Review Date: September 15, 2017 Eucrisa Description Eucrisa
More informationQuarterly pharmacy formulary change notice
MEDICAID PROVIDER BULLETIN March 2019 Quarterly pharmacy formulary change notice The formulary changes listed in the table below were reviewed and approved at the fourth quarter pharmacy and therapeutics
More informationEucrisa. Eucrisa (crisaborole) Description
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 Subject: Eucrisa Page: 1 of 7 Last Review Date: June 22, 2018 Eucrisa Description Eucrisa (crisaborole)
More informationUnitedHealthcare Pharmacy Clinical Pharmacy Programs
UnitedHealthcare Pharmacy Clinical Pharmacy Programs Program Number 2017 P 2116-3 Program Prior Authorization/Medical Necessity Medications Dupixent (dupilumab) P&T Approval Date 1/2017, 5/2017, 7/2017
More informationStep Therapy Requirements
An Independent Licensee of the Blue Cross and Blue Shield Association Step Therapy Requirements Effective: 12/01/2017 Updated 11/2017 H0302_2_2014 CMS Accepted 05/05/2014 1 ABILIFY Abilify 10 mg tablet
More informationThe safety and effectiveness of Dupixent in pediatric patients have not been established (1).
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.90.30 Subject: Dupixent Page: 1 of 6 Last Review Date: September 15, 2017 Dupixent Description Dupixent
More informationBLUE SHIELD OF CALIFORNIA MARCH 2016 STANDARD DRUG FORMULARY CHANGES
BLUE SHIELD OF CALIFORNIA MARCH 2016 STANDARD DRUG FORMULARY CHANGES Blue Shield is committed to covering safe, effective and affordable medications, so we regularly review and update our drug formularies.
More informationQuarterly pharmacy formulary change notice
Quarterly pharmacy formulary change notice Provider update Summary: Effective August 1, 2018, the preferred formulary changes detailed in the table below will apply to District of Columbia Healthy Families
More informationQuarterly pharmacy formulary change notice
Provider update Quarterly pharmacy formulary change notice Summary: The formulary changes listed in the table below were reviewed and approved at our first-quarter 2018, Pharmacy and Therapeutics Committee
More informationQuarterly Pharmacy Formulary Change Notice
MEDICAID PROVIDER BULLETIN February 26, 2015 Quarterly Pharmacy Formulary Change Notice Summary of Change: The formulary changes listed in the table below were reviewed and approved at our September 24,
More informationQuarterly pharmacy formulary change notice
The formulary changes listed in the table below apply to all Anthem HealthKeepers Plus and Anthem HealthKeepers Plus, Commonwealth Coordinated Care Plus (Anthem CCC Plus) members. These formulary changes,
More informationSee Important Reminder at the end of this policy for important regulatory and legal information.
Clinical Policy: (Enstilar, Sernivo, Taclonex) Reference Number: CP.CPA.255 Effective Date: 11.16.16 Last Review Date: 11.17 Line of Business: Commercial Revision Log See Important Reminder at the end
More informationAETNA BETTER HEALTH January 2017 Formulary Change(s)
AETNA BETTER HEALTH January 2017 Formulary Change(s) The following updates will be made to the Aetna Better Health of MI formulary on March 1, 2017 Drug Name, Strength, Dosage Form ALFUZOSIN HCL ER 10
More informationSee Important Reminder at the end of this policy for important regulatory and legal information.
Clinical Policy: (Dupixent) Reference Number: CP.HNMC.208 Effective Date: 04.11.17 Last Review Date: 11.17 Line of Business: Medicaid Medi-Cal Revision Log See Important Reminder at the end of this policy
More informationAETNA BETTER HEALTH January 2017 Formulary Change(s)
AETNA BETTER HEALTH January 2017 Formulary Change(s) The following updates will be made to the Aetna Better Health of MI formulary on February 1, 2017 Drug Name, Strength, Dosage Form IVERMECTIN 3 MG TABLET
More informationPart D Pharmacy. An Independent Licensee of the Blue Cross Blue Shield Association ( )
Part D Pharmacy 1 An Independent Licensee of the Blue Cross Blue Shield Association 044507 (12-21-2017) New MA pharmacy partner We ve selected CVS Caremark to manage our part D pharmacy benefits Providence
More information2018 Step Therapy (ST) Criteria
2018 Step Therapy (ST) Criteria Some drugs require step therapy pre-approval. This means that your doctor must have you first try a different drug to treat your medical condition before we will cover a
More informationCalgary Long Term Care Formulary
Page 1 of 10 Calgary Long Term Care Formulary Pharmacy & Therapeutics November 2018 Highlights https://www.albertahealthservices.ca/info/page4071.aspx Page 2 of 10 Contents November 2018... 3 Formulary
More informationCalgary Long Term Care Formulary
Page 1 of 14 Calgary Long Term Care Formulary Pharmacy & Therapeutics Highlights https://www.albertahealthservices.ca/info/page4071.aspx Page 2 of 14 Contents... 3 Formulary Changes (Additions, Changes,
More informationHigh-Cost Drug Exclusions
PHARMACY SERVICES High-Cost Exclusions The high cost medications listed below are excluded from coverage because lower cost similar alternatives are available. To help you get the best health benefit at
More informationBlue Cross and Blue Shield of Minnesota GenRx Formulary Updates
Blue Cross and Blue Shield of Minnesota GenRx Formulary Updates April 2018 TRADE NAME (generic name) or generic name Brand/Generic Description of Change abacavir sulfate soln 20 mg/ml (base equiv) Generic
More informationDEPARTMENT OF DEFENSE PHARMACY AND THERAPEUTICS COMMITTEE RECOMMENDATIONS INFORMATION FOR THE UNIFORM FORMULARY BENEFICIARY ADVISORY PANEL
DEPARTMENT OF DEFENSE PHARMACY AND THERAPEUTICS COMMITTEE RECOMMENDATIONS INFORMATION FOR THE UNIFORM FORMULARY BENEFICIARY ADVISORY PANEL I. UNIFORM FORMULARY REVIEW PROCESS Under 10 United States Code
More informationCENTENE PHARMACY AND THERAPEUTICS NEW DRUG REVIEW 3Q17 July August
BRAND NAME Dupixent GENERIC NAME dupilumab MANUFACTURER Regeneron DATE OF APPROVAL March 28, 2017 PRODUCT LAUNCH DATE First week of April 2017 REVIEW TYPE Review type 1 (RT1): New Drug Review Full review
More informationTABLE OF CONTENTS (Click on a link below to view the section.)
Follow the links below to access the complete formularies for Plans: Health Plan Acne Allergy Allergic Anaphylactic Reaction Allergic Conjunctivitis Allergic Rhinitis Asthma Atopic Dermatitis Behavioral
More informationStep Therapy Criteria (Criteria for Step Therapy-2 [ST-2] Drugs)
CareAdvantage CMC 2018 Formulary Supplement II (List of Covered Drugs) Step Therapy Criteria (Criteria for Step Therapy-2 [ST-2] Drugs) Formulary ID: 00018157 Formulary Version:11 19 CMS Approved: 08/21/2018
More informationAmerigroup Washington, Inc. to conduct postservice reviews of certain modifiers and services
Provider News Bulletin Amerigroup Washington, Inc. https://providers.amerigroup.com/ Medicaid providers: 1-800-454-3730 Medicare providers: 1-866-805-4589 December 2017 Table of Contents Special Announcement:
More information2017 Formulary Changes Year to Date
2017 Formulary Changes Year to Date Health Choice Arizona may add or remove drugs from our formulary during the year. If we remove drugs from our formulary, add prior authorization, quantity limits and/or
More informationClinical Policy: Dupilumab (Dupixent) Reference Number: ERX.SPA.49 Effective Date:
Clinical Policy: (Dupixent) Reference Number: ERX.SPA.49 Effective Date: 06.01.17 Last Review Date: 02.19 Revision Log See Important Reminder at the end of this policy for important regulatory and legal
More informationChildren s Hospital Of Wisconsin
Children s Hospital Of Wisconsin Co-Management Guidelines To support collaborative care, we have developed guidelines for our community providers to utilize when referring to, and managing patients with,
More informationUpdates to your prescription benefits
Updates to your prescription benefits Effective Jan. 1, 2019 Traditional Three-Tier PDL Update Summary Within the Prescription Drug List (PDL), medications are grouped by tier. The tier indicates the amount
More informationDupixent (dupilumab)
Dupixent (dupilumab) Line(s) of Business: HMO; PPO; QUEST Integration Effective Date: TBD POLICY A. INDICATIONS The indications below including FDA-approved indications and compendial uses are considered
More informationStep Therapy Medications
Step Therapy Medications Step Therapy (ST PA ) is an automated form of prior authorization. It encourages the use of therapies that should be tried first, before other treatments are covered, based on
More informationTopical Immunomodulators
Texas Prior Authorization Program Clinical Edit Criteria Drug/Drug Class Topical Immunomodulators Clinical Edit Information Included in this Document Topical Immunomodulators Elidel and Protopic 0.03%
More informationHigh-Cost Drug Exclusions
Pharmacy Services High-Cost Exclusions The high cost medications listed below are excluded from coverage because lower cost similar alternatives are available. To help you get the best health benefit at
More informationTABLE OF CONTENTS (Click on a link below to view the section.)
Follow the links below to access the complete formularies for Plans: Buckeye Health Plan Acne Allergy Allergic Anaphylactic Reaction Allergic Conjunctivitis Allergic Rhinitis Asthma Atopic Dermatitis Behavioral
More informationPharmacologic Treatment of Atopic Dermatitis
J KMA Pharmacotherapeutics Pharmacologic Treatment of Atopic Dermatitis Chun Wook Park, MD Department of Dermatology, Hallym University College of Medicine E mail : dermap@paran.com J Korean Med Assoc
More informationTexas Children's Hospital Dermatology Service PCP Referral Guidelines- Atopic Dermatitis (AD)
Diagnosis: ATOPIC DERMATITIS (AD) Texas Children's Hospital Dermatology Service PCP Referral Guidelines- Atopic Dermatitis (AD) PATIENT ADVICE: Unfortunately, there is no cure for atopic dermatitis, so
More informationUpdates to your prescription benefits
Updates to your prescription benefits Effective January 1, 2019 Update Summary Within the Prescription Drug List (PDL), medications are grouped by tier. The tier indicates the amount you pay when you fill
More informationConnecticut Medicaid P&T Meeting Minutes December 2, 2010
Connecticut Medicaid P&T Meeting Minutes December 2, 2010 The meeting started at 6:34 pm Attendance Present Members: Carl Sherter, MD Peggy Manning Memoli, Pharm D Eric Einstein, MD Charles Thompson, MD
More informationWellCare s South Carolina Preferred Drug List Update
WellCare s South Carolina Preferred Drug List Update This is a list of changes to our preferred drug list. These are a result of the latest WellCare Pharmacy & Therapeutics meeting held on 09/21/2017.
More informationTexas Prior Authorization Program Clinical Edit Criteria
Texas Prior Authorization Program Clinical Edit Criteria Drug/Drug Class Clinical Edit Information Included in this Document Drugs requiring prior authorization: the list of drugs requiring prior authorization
More informationSan Francisco Health Plan (SFHP)
San Francisco Health Plan (SFHP) The following changes to SFHP formulary and prior authorization criteria were reviewed and approved by the SFHP Pharmacy and Therapeutics (P&T) Committee on 07/18/2018.
More informationBlueLink TPA FlexRx Updates
BlueLink TPA FlexRx Updates April 2018 TRADE NAME (generic name) or generic name abacavir sulfate soln 20 mg/ml (base equiv) Generic Addition, generic for ZIAGEN alclometasone dipropionate cream 0.05%
More informationALLERGIC RHINITIS-NASAL
ALLERGIC RHINITIS-NASAL FLUNISOLIDE Patient needs to have paid claims for any one of the following Step 1 drugs: NasaCort OTC, fluticasone Rx, fluticasone OTC, Budesonide OTC. Prior to filling the Step
More informationAlprazolam 0.25mg, 0.5mg, 1mg tablets
Presbyterian Senior Care (HMO) / Presbyterian MediCare PPO Quantity Limits Effective November 1, 2014 For the most recent list of drugs or other questions, please contact the Presbyterian Customer Service
More informationSee Important Reminder at the end of this policy for important regulatory and legal information.
Clinical Policy: (Dupixent) Reference Number: CP.PHAR.336 Effective Date: 05.01.17 Last Review Date: 02.19 Line of Business: Commercial, HIM, Medicaid Coding Implications Revision Log See Important Reminder
More informationLABEL NAME CHANGE EFFECTIVE DATE ARCALYST 220 MG INJECTION
LABEL NAME CHANGE EFFECTIVE DATE ARCALYST 220 MG INJECTION Added Prior Authorization 7/1/17 CORLANOR 5 MG TABLET Added Prior Authorization 7/1/17 CORLANOR 7.5 MG TABLET Added Prior Authorization 7/1/17
More informationQuarterly pharmacy formulary change notice
Provider Bulletin June 24, 2016 Summary of change The Pharmacy and Therapeutics Committee reviewed and approved the formulary changes listed in the table below on March 29, 2016. What this means to you
More informationTexas Prior Authorization Program Clinical Edit Criteria
Texas Prior Authorization Program Clinical Edit Criteria Drug/Drug Class Thiazolidinediones Clinical Edit Information Included in this Document Thiazolidinediones Drugs requiring prior authorization: the
More informationTABLE OF CONTENTS (Click on a link below to view the section.)
Follow the links below to access the complete formularies for Plans: Health Plan Acne Allergy Allergic Anaphylactic Reaction Allergic Conjunctivitis Allergic Rhinitis Asthma Atopic Dermatitis Behavioral
More informationSpending on Individuals with Type 1 Diabetes and the Role of Rapidly Increasing Insulin Prices
Spending on Individuals with Type 1 Diabetes and the Role of Rapidly Increasing Insulin Prices Authors: Jean Fuglesten Biniek William Johnson January 2019 Insulin Prices Were the Primary Driver of Rapid
More informationHealth Partners Medicare Prime 2019 Formulary Changes
Health Partners Medicare Prime 2019 Formulary Changes Changes occur, for example, because new drugs come on the market, a drug is moved to a different cost-sharing level (tier), or a generic version becomes
More informationDrug Formulary Update, April 2017 Commercial and State Programs
Drug Formulary Update, April 2017 Commercial and State Programs Updates to the HealthPartners Commercial and State Program Drug Formularies are listed below. Updates apply to all Commercial groups (PreferredRx,
More informationConversion from lantus to tresiba
Conversion from lantus to tresiba Search dosages for Diabetes Type 2 and Diabetes Type 1; plus renal, liver and. Forecast your health care. Every time you have a symptom or are diagnosed of a condition,
More informationQuarterly pharmacy formulary change notice
Serving Hoosier Healthwise, Healthy Indiana Plan and Hoosier Care Connect May 2018 Quarterly pharmacy formulary change notice Effective May 1, 2018, the preferred formulary changes detailed in the table
More informationClinical pharmacology review for primary health care providers: II. Steroids
TCP 2015;23(1):15-20 http://dx.doi.org/10.12793/tcp.2015.23.1.15 Clinical pharmacology review for primary health care providers: II. Steroids TUTORIAL Seunghoon Han* Department of Clinical Pharmacology
More informationANTIEMETICS STEP. Step Therapy Requirements Effective April 1, 2019
Step Therapy Requirements Effective April 1, 2019 ANTIEMETICS STEP Sancuso 3.1 mg/24 hour transdermal patch Zuplenz 4 mg oral soluble film Zuplenz 8 mg oral soluble film COVERAGE OF CERTAIN BRAND NAME
More informationLantus levemir conversion
Lantus levemir conversion Search Learn about starting insulin-naïve patients with type 2 diabetes on Levemir. Read Important Safety & Prescribing Info on the HCP Website. Lantus and Levemir have a variety
More informationTABLE OF CONTENTS (Click on a link below to view the section.)
Follow the links below to access the complete formularies for Plans: Health Plan Acne Allergy Allergic Anaphylactic Reaction Allergic Conjunctivitis Allergic Rhinitis Asthma Atopic Dermatitis Behavioral
More information2015 Medicare Step Therapy Criteria. Last Modified: 12/31/2014 Last Submitted to CMS: 10/29/2014
2015 Medicare Step Therapy Criteria Last Modified: 12/31/2014 Last Submitted to CMS: 10/29/2014 1 Table of Contents AMITIZA, LINZESS... 3 ANTIDEPRESSANTS - Viibryd / Pexeva / Pristiq / Desvenlafaxine...
More information84:00. Skin and Mucous Membrane Agents. 84:00 Skin and Mucous Membrane Agents
Skin and Mucous Membrane Agents Skin and Mucous Membrane Agents COMPOUND PRESCRIPTION 00000999119 00000999112 COMPOUND - RETINOIC ACID (TRETINOIN) () MISCELLANEOUS COMPOUND To be used when the compound
More information2017 Step Therapy (ST) Criteria
2017 Step Therapy (ST) Criteria Some drugs require step therapy pre-approval. This means that your doctor must have you first try a different drug to treat your medical condition before we will cover a
More informationDrug Use Criteria: Exogenous Insulin Products
Texas Vendor Program Use Criteria: Exogenous Products Publication History 1. Developed June 2017. Notes: Information on indications for use or diagnosis is assumed to be unavailable. All criteria may be
More informationInsulin Prior Authorization with optional Quantity Limit Program Summary
Insulin Prior Authorization with optional Quantity Limit Program Summary 1-13,16-19, 20 FDA LABELED INDICATIONS Rapid-Acting Insulins Humalog (insulin lispro) NovoLog (insulin aspart) Apidra (insulin glulisine)
More informationDate: October 3, 2017 To: Participating Providers From: YourCare Health Plan Provider Relations Subject: 2018 Formulary Changes
Date: October 3, 2017 To: Participating Providers From: YourCare Health Plan Provider Relations Subject: 2018 Formulary Changes 2018 Formulary-UM Changes What does this mean now, and for 2018? A number
More information2015 Step Therapy Prior Authorization Medical Necessity Guidelines
Tufts Health Unify 2015 Step Therapy Prior Authorization Medical Necessity Guidelines Effective: 01/01/2015 Updated: 10/01/2015 Tufts Health Plan P.O. Box 9194 Watertown, MA 02471-9194 Phone: 855-393-3154
More informationADMELOG, NOVOLIN, NOVOLOG, and FIASP
ADMELOG, NOVOLIN, NOVOLOG, and FIASP Coverage for services, procedures, medical devices and drugs are dependent upon benefit eligibility as outlined in the member's specific benefit plan. This Pharmacy
More informationPHARMA-MEDIC SERVICES INC. POLICY MANUAL
PHARMA-MEDIC SERVICES INC. POLICY MANUAL SUBJECT: INDEX: P.5.a.iii Automatic-Therapeutic Substitution DATE: June 1/2011 REVISED: March 2, 2015., Feb 2017. PROCEDURE: 1. Long term care homes use the Manitoba
More informationKentucky Pharmacy and Therapeutics Advisory Committee meeting minutes Triton Park Blvd., Louisville, KY April 26, p.m.-3 p.m.
Kentucky Pharmacy and Therapeutics Advisory Committee meeting minutes 13550 Triton Park Blvd., Louisville, KY 40223 April 26, 2017 1 p.m.-3 p.m. Attendees: Andrew Rudd Steven Broudy Setifah Jordan Keith
More information8/13/2016. Insulin Basics. Rapid-Acting Insulin Analogs. Current Insulin Products and Pens. Basal Insulin Analogs. History of Insulin Therapy
Insulin Basics Anabolic hormone involved in metabolism Following carbohydrate ingestion insulin release is stimulated Suppresses hepatic glucose production Stimulates peripheral glucose uptake Commercially-available
More informationHigh-Cost Drug Exclusions
PHARMACY SERVICES High-Cost Exclusions The high cost medications listed below are excluded from coverage because lower cost similar alternatives are available. To help you get the best health benefit at
More informationTHERAPEUTIC AREA NAME STRENGTH DOSAGE FORM
Value Based Tier Drugs are selected for the management of Asthma, Diabetes, Hypertension and Hyperlipidemia. These drugs are covered at no charge or at a reduced cost share. Medications are under continual
More informationAetna Better Health of Illinois Medicaid Formulary Updates
October 2017 o DOXYLAMINE SUCCINATE 25mg-QL o DULOXETINE CAP 40MG DR-QL o GUANFACIN ER TABS (all strengths)-ql o TOBRAMYCIN NEBU SOLUTION- PA August 2017 Aetna Better Health of Illinois Medicaid 2017 Formulary
More informationAlameda Alliance for Health Pharmacy & Therapeutics (P&T) Committee Decisions
Alameda Alliance for Health FORMULARY UPDATE Effective: October 27, 2017. Drugs notated with an * have an undetermined implementation date Alameda Alliance for Health Pharmacy & Therapeutics (P&T) Committee
More informationCalgary Zone LTC Formulary Autosubstitution List
Calgary Zone LTC Formulary Autosubstitution List PURPOSE ASL-01 In order to simplify drug therapy, orders for one medication may be automatically substituted using a different, but therapeutically equivalent
More informationDrug Effectiveness Review Project Summary Report Long acting Insulins
Copyright 2012 Oregon State University. All Rights Reserved Drug Use Research & Management Program Oregon State University, 500 Summer Street NE, E35 Salem, Oregon 97301-1079 Phone 503-947-5220 Fax 503-947-1119
More informationTHERAPEUTIC AREA NAME STRENGTH DOSAGE FORM
Value Based Tier Drugs are selected for the management of Asthma, Diabetes, Hypertension and Hyperlipidemia. These drugs are covered at no charge or at a reduced cost share. Medications are under continual
More informationDrugs That Require Step Therapy (ST)
Saver Drugs That Require Step Therapy (ST) In some cases, Express Scripts Medicare (PDP) requires you to first try certain drugs to treat your medical condition before we will cover another drug for that
More informationCalgary Zone LTC Formulary Autosubstitution List
Calgary Zone LTC Formulary Autosubstitution List PURPOSE ASL-01 In order to simplify drug therapy, orders for one medication may be automatically substituted using a different, but therapeutically equivalent
More information2018 Step Therapy (ST) Criteria
2018 Step Therapy (ST) Criteria Some drugs require step therapy pre-approval. This means that your doctor must have you first try a different drug to treat your medical condition before we will cover a
More informationAlameda Alliance for Health Pharmacy & Therapeutics (P&T) Committee Decisions
Alameda Alliance for Health FORMULARY UPDATE Effective: April 21, 2017. Drugs notated with an * have an undetermined implementation date Alameda Alliance for Health Pharmacy & Therapeutics (P&T) Committee
More informationDrugs That Require Step Therapy (ST)
Saver Drugs That Require Step Therapy (ST) In some cases, Express Scripts Medicare (PDP) requires you to first try certain drugs to treat your medical condition before we will cover another drug for that
More information